Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for UroGen Pharma (URGN) over the last 7 years, with Q3 2025 value amounting to $296.7 million.

  • UroGen Pharma's Total Non-Current Liabilities rose 857.47% to $296.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $296.7 million, marking a year-over-year increase of 857.47%. This contributed to the annual value of $290.7 million for FY2024, which is 2096.88% up from last year.
  • Latest data reveals that UroGen Pharma reported Total Non-Current Liabilities of $296.7 million as of Q3 2025, which was up 857.47% from $298.3 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Total Non-Current Liabilities peaked at $298.3 million during Q2 2025, and registered a low of $18.2 million during Q1 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $230.8 million (2023), whereas its average is $208.5 million.
  • In the last 5 years, UroGen Pharma's Total Non-Current Liabilities skyrocketed by 88839.39% in 2022 and then soared by 486.73% in 2024.
  • Over the past 5 years, UroGen Pharma's Total Non-Current Liabilities (Quarter) stood at $108.5 million in 2021, then surged by 104.59% to $222.0 million in 2022, then increased by 8.27% to $240.3 million in 2023, then rose by 20.97% to $290.7 million in 2024, then rose by 2.04% to $296.7 million in 2025.
  • Its last three reported values are $296.7 million in Q3 2025, $298.3 million for Q2 2025, and $290.3 million during Q1 2025.